Skip To Main Content
Angelo Lombardo on Muck Rack

Angelo Lombardo

As seen in: Nature, Control Engineering Magazine, Ontario OUT OF DOORS Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Angelo

Contact Angelo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Selection of human hematopoietic stem cells bearing the intended functional edit by transient AND-gate reporters

|
By Daniele Canarutto, Martina Fiumara, Vigneshwaran Venkatesan, Chiara Gaddoni, Kohei Shiroshita, Angelica Varesi, Luisa Albano, Gabriele Pelosi, Alfredo Silva, Claudia Firrito, Giulia Schiroli, Deborah Cipria, Stefano Beretta, Angelo Amabile, Anna Villa, Erika Zonari, Bernhard Gentner, Angelo Lombardo, Pietro Genovese, Samuele Ferrari, Luigi Naldini
| Nature Verified
Abstract Targeted genomic integration of gene-sized cassettes into hematopoietic stem and progenitor cells (HSPCs) for genetic disease treatment is constrained by the low efficiency of homology-directed repair (HDR) and frequent unintended genetic changes at the editing site.
Open in Who Shared Issue with article?

A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels - Nature Medicine

|
By Frédéric Tremblay, Erica M Hildebrand, Angelo Lombardo, Ari E. Friedland
| Nature Verified
Abstract Epigenetic editing holds the promise of durable therapeutic effects by silencing disease-causing genes without changing the underlying DNA sequence. In this study, we designed an epigenetic editor to target human PCSK9 and thereby induce DNA methylation at this locus. A single administration of lipid nanoparticles encapsulating mRNA encoding this epigenetic editor was sufficient to drive near-complete silencing of human PCSK9 in transgenic mice.
Open in Who Shared Issue with article?

miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease - Leukemia

|
By Silvia Nucera, Grazia Fazio, Matteo Maria Naldini, Angelo Lombardo, Orietta Spinelli, Fabio Ciceri, Giovanni Cazzaniga
| Nature Verified
Abstract Complete elimination of B-cell acute lymphoblastic leukemia (B-ALL) by a risk-adapted primary treatment approach remains a clinical key objective, which fails in up to a third of patients. Recent evidence has implicated subpopulations of B-ALL cells with stem-like features in disease persistence. We hypothesized that microRNA-126, a core regulator of hematopoietic and leukemic stem cells, may resolve intratumor heterogeneity in B-ALL and uncover therapy-resistant subpopulations.
Open in Who Shared Issue with article?
See all 7 articles